| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.61 [0.41, 0.92] | | < 1 | | 85% | 4 studies (4/-) | 99.1 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.46 [0.36, 0.59] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.42 [0.33, 0.53] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.53 [0.35, 0.79] | | < 1 | | 89% | 3 studies (3/-) | 99.9 % | low | not evaluable | high | important | - |
| DOR (extension) | 3.45 [1.46, 8.18] | | > 1 | | 0% | 1 study (1/-) | 99.8 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.16 [1.06, 4.39] | | > 1 | | 90% | 4 studies (4/-) | 98.3 % | low | not evaluable | high | non important | - |
| objective responses (ORR) (extension) | 4.50 [2.79, 7.25] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 1.35 [0.48, 3.76] | | < 1 | | 73% | 2 studies (2/-) | 28.5 % | some concern | not evaluable | moderate | non important | - |
| AE (grade 3-4) | 1.26 [0.58, 2.72] | | < 1 | | 89% | 2 studies (2/-) | 28.2 % | some concern | not evaluable | moderate | non important | - |
| AE leading to death (grade 5) | 1.53 [0.86, 2.73] | | < 1 | | 0% | 3 studies (3/-) | 7.5 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 1.37 [0.38, 5.00] | | < 1 | | 84% | 3 studies (3/-) | 31.7 % | low | not evaluable | high | non important | - |
| AE leading to treatment discontinuation (grade 3-4) | 0.61 [0.29, 1.28] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 1.53 [0.36, 6.48] | | < 1 | | 96% | 2 studies (2/-) | 28.1 % | some concern | not evaluable | moderate | non important | - |
| SAE (grade 3-4) | 0.74 [0.47, 1.17] | | < 1 | | 0% | 1 study (1/-) | 90.4 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 1.20 [0.86, 1.66] | | < 1 | | 0% | 2 studies (2/-) | 14.4 % | low | not evaluable | high | non important | - |
| STRAE (grade 3-4) | 0.99 [0.44, 2.27] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.93 [0.60, 1.43] | | < 1 | | 0% | 2 studies (2/-) | 63.7 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 0.95 [0.43, 2.13] | | < 1 | | 81% | 2 studies (2/-) | 54.6 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 7.00 [0.86, 57.23] | | < 1 | | 0% | 1 study (1/-) | 3.6 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Alopecia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Arthralgia TRAE (grade 3-4) | 1.40 [0.48, 4.06] | | < 1 | | 0% | 2 studies (2/-) | 26.8 % | low | not evaluable | high | non important | - |
| Asthenia TRAE (grade 3-4) | 1.79 [0.39, 8.22] | | < 1 | | 0% | 2 studies (2/-) | 22.8 % | low | not evaluable | high | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Chorioretinopathy TRAE (grade 3-4) | 0.61 [0.02, 18.27] | | < 1 | | 0% | 1 study (1/-) | 61.1 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Cough TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.48 [0.04, 5.47] | | < 1 | | 0% | 2 studies (2/-) | 72.1 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.69 [0.24, 2.02] | | < 1 | | 0% | 2 studies (2/-) | 74.9 % | low | not evaluable | high | non important | - |
| Dry skin TRAE (grade 3-4) | 2.66 [0.23, 30.36] | | < 1 | | 0% | 2 studies (2/-) | 21.7 % | low | not evaluable | high | non important | - |
| Erythema TRAE (grade 3-4) | 7.41 [0.37, 148.78] | | < 1 | | 0% | 1 study (1/-) | 9.8 % | NA | not evaluable | | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.98 [0.02, 49.62] | | < 1 | | 0% | 1 study (1/-) | 50.4 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 1.19 [0.09, 16.28] | | < 1 | | 47% | 2 studies (2/-) | 45.0 % | low | not evaluable | high | non important | - |
| Headache TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 3.94 [0.18, 87.81] | | < 1 | | 0% | 1 study (1/-) | 19.6 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 3.26 [0.33, 32.32] | | < 1 | | 0% | 2 studies (2/-) | 15.8 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 1.00 [0.06, 16.02] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.00 [0.18, 22.23] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 0.99 [0.64, 1.52] | | < 1 | | 0% | 1 study (1/-) | 52.3 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.12 [0.01, 2.33] | | < 1 | | 0% | 1 study (1/-) | 91.7 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 1.37 [0.79, 2.37] | | < 1 | | 0% | 2 studies (2/-) | 13.0 % | low | not evaluable | high | non important | - |
| Myalgia TRAE (grade 3-4) | 1.92 [0.25, 14.93] | | < 1 | | 0% | 2 studies (2/-) | 26.8 % | low | not evaluable | high | non important | - |
| Nausea TRAE (grade 3-4) | 0.25 [0.04, 1.62] | | < 1 | | 0% | 2 studies (2/-) | 92.6 % | low | not evaluable | high | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.92] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.16 [0.01, 3.29] | | < 1 | | 0% | 1 study (1/-) | 87.9 % | NA | not evaluable | | non important | - |
| Paraesthesia TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 4.92 [0.22, 109.67] | | < 1 | | 0% | 1 study (1/-) | 16.0 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 2.29 [0.32, 16.34] | | < 1 | | 0% | 2 studies (2/-) | 20.5 % | low | not evaluable | high | non important | - |
| Pyrexia TRAE (grade 3-4) | 1.04 [0.24, 4.45] | | < 1 | | 0% | 2 studies (2/-) | 48.0 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 1.00 [0.54, 1.83] | | < 1 | | 0% | 2 studies (2/-) | 50.3 % | low | not evaluable | high | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.05 [0.00, 0.82] | | < 1 | | 0% | 1 study (1/-) | 98.1 % | NA | not evaluable | | non important | - |
| Vitiligo TRAE (grade 3-4) | 1.00 [0.02, 50.40] | | < 1 | | 0% | 1 study (1/-) | 50.1 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.58 [0.14, 2.41] | | < 1 | | 0% | 2 studies (2/-) | 77.1 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 4.04 [1.13, 14.45] | | < 1 | | 0% | 1 study (1/-) | 1.6 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.10 [0.01, 1.78] | | < 1 | | 0% | 1 study (1/-) | 94.0 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.98 [0.14, 7.01] | | < 1 | | 0% | 1 study (1/-) | 50.7 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 1.97 [0.07, 58.81] | | < 1 | | 0% | 1 study (1/-) | 35.0 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 14.32 [1.87, 109.52] | | < 1 | | 0% | 1 study (1/-) | 0.5 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 4.00 [0.84, 18.98] | | < 1 | | 0% | 1 study (1/-) | 4.1 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 3.90 [1.44, 10.57] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| Headache AE (grade 3-4) | 1.97 [0.18, 21.82] | | < 1 | | 0% | 1 study (1/-) | 29.2 % | NA | not evaluable | | non important | - |
| Hypothyroidism AE (grade 3-4) | 1.22 [0.02, 61.84] | | < 1 | | 0% | 1 study (1/-) | 46.1 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 1.39 [0.61, 3.18] | | < 1 | | 0% | 1 study (1/-) | 21.7 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Peripheral oedema AE (grade 3-4) | 4.97 [0.58, 42.77] | | < 1 | | 0% | 1 study (1/-) | 7.3 % | NA | not evaluable | | non important | - |
| Pruritus AE (grade 3-4) | 5.93 [0.30, 118.96] | | < 1 | | 0% | 1 study (1/-) | 12.5 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 7.94 [0.42, 150.76] | | < 1 | | 0% | 1 study (1/-) | 8.6 % | NA | not evaluable | | non important | - |
| Rash AE (grade 3-4) | 7.00 [0.86, 57.23] | | < 1 | | 0% | 1 study (1/-) | 3.6 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.26] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.55 [0.66, 3.64] | | < 1 | | 0% | 1 study (1/-) | 15.7 % | NA | not evaluable | | non important | - |
| Weight decreased AE (grade 3-4) | 0.98 [0.06, 15.76] | | < 1 | | 0% | 1 study (1/-) | 50.5 % | NA | not evaluable | | non important | - |
